Jason Elinoff, M.D.

Investigator

Critical Care Medicine Department

NIH Clinical Center

Building 10, Room 4D03
10 Center Drive
Bethesda, MD 20892

301-402-4846

elinoffj@cc.nih.gov

Research Topics

PAH is characterized by dysregulated cell proliferation and infiltration of activated inflammatory cells leading to progressive narrowing and obliteration of the distal pulmonary arteries. Persistent increases in pulmonary vascular resistance lead to right heart failure and ultimately death. While current therapeutics reduce pulmonary arterial pressure, and increase time to death or transplant, median survival is remains only five to seven years from the time of diagnosis. Unlike selective pulmonary vasodilators alone, approaches directed at inflammatory vascular remodeling have the potential to arrest or even reverse the disease.

Dr. Elinoff's research focus is the contributions of pulmonary vascular endothelium and immune effector cells to the development and progression of PAH. Current work includes in vitro profiling of human pulmonary artery endothelial cells with heterogeneous PAH-associated molecular defects in order to investigate molecular mechanisms that can exploited therapeutically. The overarching goal of the program is to translate basic science and pre-clinical studies to early phase therapeutic trials in PAH patients.

Honors and Awards

  • NIH Bench-to-Bedside Award, "Role of AR and ER Signaling in Pulmonary Arterial
  • Hypertension", 2011
  • NIH Clinical Center Director's Award, 2010
  • Alpha Omega Alpha, University of Chicago Pritzker School of Medicine, 2004
  • HHMI Continued Fellowship for Medical Studies 2003-2004
  • HHMI-NIH Research Scholar 2002
  • Everett S. Wallis Prize in Organic Chemistry, Princeton University, 1999
  • Magna Cum Laude, Department of Chemistry, Princeton University, 1999

Biography

Dr. Jason Elinoff is currently a Tenure-Track Investigator in the NIH Clinical Center's Critical Care Medicine Department and serves as the Co-Director of the CCMD Translational Pulmonary Arterial Hypertension Program.

Dr. Elinoff earned his undergraduate degree in Chemistry from Princeton University and his degree in Medicine from the University of Chicago Pritzker School of Medicine. He went on to complete internship and residency training in Internal Medicine at the Massachusetts General Hospital.

Dr. Elinoff completed fellowship training in Critical Care Medicine at the NIH Clinical Center and Pulmonary and Critical Care Medicine at Johns Hopkins University.

Selected Publications

  1. Elinoff JM, Chen LY, Dougherty EJ, Awad KS, Wang S, Biancotto A, Siddiqui AH, Weir NA, Cai R, Sun J, Preston IR, Solomon MA, Danner RL. Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling. Cardiovasc Res. 2018;114(1):65-76.

  2. Awad KS, Elinoff JM, Wang S, Gairhe S, Ferreyra GA, Cai R, Sun J, Solomon MA, Danner RL. Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2016;310(2):L187-201.

  3. Rhodes CJ, Otero-Núñez P, Wharton J, Swietlik EM, Kariotis S, Harbaum L, Dunning MJ, Elinoff JM, Errington N, Thompson AAR, Iremonger J, Coghlan JG, Corris PA, Howard LS, Kiely DG, Church C, Pepke-Zaba J, Toshner M, Wort SJ, Desai AA, Humbert M, Nichols WC, Southgate L, Trégouët DA, Trembath RC, Prokopenko I, Gräf S, Morrell NW, Wang D, Lawrie A, Wilkins MR. Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. Am J Respir Crit Care Med. 2020;202(4):586-594.

  4. Wang S, Awad KS, Elinoff JM, Dougherty EJ, Ferreyra GA, Wang JY, Cai R, Sun J, Ptasinska A, Danner RL. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY. J Biol Chem. 2015;290(32):19544-57.

  5. Elinoff JM, Rame JE, Forfia PR, Hall MK, Sun J, Gharib AM, Abd-Elmoniem K, Graninger G, Harper B, Danner RL, Solomon MA. A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial. Trials. 2013;14:91.


This page was last updated on September 1st, 2020